Royalty Pharma (NASDAQ:RPRX) PT Raised to $50.00

Royalty Pharma (NASDAQ:RPRX – Get Rating) had its target price lifted by investment analysts at Morgan Stanley from $48.00 to $50.00 in a note issued to investors on Monday, The Fly reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective suggests a potential upside of 36.87% from […]

Related Keywords

United States ,Marshall Urist ,Roryb Riggs ,Morgan Stanley ,Voya Investment Management ,Victory Capital Management Inc ,Securities Exchange Commission ,Macquarie Group Ltd ,United Capital Financial Advisers ,Royalty Pharma ,Get Rating ,Director Rory ,Exchange Commission ,Ivy Capital Management ,Capital Management ,Investment Management ,Capital Financial Advisers ,Royalty Pharma Daily ,Nasdaq Rprx ,Rprx ,Finance ,76028h20 ,Boost Price Target ,